Porphyrin-containing cationic polymer, tissue marking agent containing the same, and photosensitizer

A copolymer with quaternary ammonium and porphyrin units addresses visibility and persistence issues in tumor marking and PDT, offering precise, long-lasting site identification and improved PDT efficacy.

JP7593579B2Active Publication Date: 2024-12-03NAT INST FOR MATERIALS SCI +1
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
JP2023539644
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2021-08-03
Filing Date
2022-03-30
Publication Date
2024-12-03
Estimated Expiration
2042-03-30

AI Technical Summary

Technical Problem

Conventional marking agents for tumor sites in gastrointestinal cancer lack visibility and persistence, and photodynamic therapy (PDT) photosensitizers diffuse throughout the body, affecting patient quality of life and treatment efficacy.

Method used

A copolymer containing a quaternary ammonium cation and a porphyrin compound is developed, which binds to tissue sites, allowing long-term marking and localized photosensitizer delivery for PDT, enabling clear site identification and enhanced therapeutic effect.

Benefits of technology

The copolymer provides long-lasting tissue binding and fluorescence for accurate marking, reduces systemic photosensitizer diffusion, and enhances PDT efficacy with reduced dosage, improving surgical precision and patient comfort.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007593579000008
    Figure 0007593579000008
  • Figure 0007593579000009
    Figure 0007593579000009
  • Figure 0007593579000010
    Figure 0007593579000010
Patent Text Reader

Abstract

The present invention provides a novel copolymer which is able to be used as a marking agent for a specific part of a biological tissue, and which is also able to be used as a photosensitizer that is topically administered in PDT therapy. A copolymer which comprises a repeating unit represented by formula (I) and a repeating unit represented by formula (II).
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a copolymer containing a repeating unit having a quaternary ammonium cation and a repeating unit having a porphyrin compound or a salt thereof, a tissue marking agent and a photosensitizer containing the same, and methods for producing the same. [Background technology]

[0002] In surgery to remove cancer tissue, the amount of normal tissue that can be left behind is important for maintaining normal organ function after surgery. For this reason, tumor sites are marked before surgery to avoid removing unnecessary tissue. In particular, gastrointestinal cancers are usually present inside the gastrointestinal tract, and there is a need for a marking method that can identify the tumor site from the outside of the gastrointestinal tract.

[0003] Conventionally, when performing surgery for gastrointestinal cancer, the tumor site would be marked before surgery by injecting ink into the tumor site using an endoscope (ink injecting method) or by placing a clip with a part that turns color with a fluorescent dye or the like (see Non-Patent Document 1).

[0004] However, marking with ink drops has poor visibility because it is difficult to distinguish from the color of tissue, and it is also difficult to identify the tumor site from outside the digestive tract. In addition, the injected ink spreads in a short time, making it difficult to determine the boundary between the tumor site and normal tissue. In addition, considering the spread of the ink, the marking agent must be injected at least one day before surgery, which makes it difficult to schedule surgery.

[0005] Marking with clips cannot be used in laparoscopic surgery because there is a problem that the clips can get caught when trying to cut the tissue with an automatic stapler. Also, the clips can come off due to the vigorous contraction (peristalsis) of the digestive tract.

[0006] In response to these problems with the ink-drop method and the clipping method, a method has been proposed in which indocyanine green (ICG) is injected into the submucosal layer immediately below the site of a rectal cancer tumor before surgery to mark the tumor site (Non-Patent Document 2). With this method, it is possible to recognize the tumor site from outside the digestive tract by irradiating it with near-infrared light, and there are no problems associated with the clipping method. However, even with this method, there are still problems such as the fluorescent area varying due to the diffusion of the dye, making the resection line unclear (see the discussion in Non-Patent Document 2).

[0007] In breast cancer, which is rich in adipose tissue, a marking preparation for marking the site to be resected before surgery has been proposed that contains a dye such as methylene blue and a thickener (Patent Document 1). In this marking preparation, a dye such as methylene blue is used to clearly distinguish the marking site from tissue and blood, and a thickener is added to increase the viscosity of the marking preparation to suppress the diffusion of the dye even in the adipose tissue of the breast. However, even in this marking preparation, the dye is not bound to the tumor site, so the diffusion prevention effect is temporary and the dye diffuses in a relatively short time. In addition, this marking preparation does not use a fluorescent dye with breast cancer in mind, and when applied to gastrointestinal cancer, the tumor site cannot be recognized from the outside of the tissue.

[0008] On the other hand, photodynamic therapy (PDT) has been developed for cancer treatment, in which a photosensitizer is administered into the blood vessels of a cancer patient, where it accumulates in the cancer or tumor tissue, and then irradiated with light of a specific wavelength to generate active oxygen and specifically kill only cancer cells. PDT is a minimally invasive cancer treatment that can selectively kill only tumor cells through a photochemical reaction, but it is usually administered intravascularly, and the photosensitizer is diffused throughout the body. For this reason, patients who undergo PDT are required to strictly limit light shielding, and there are concerns that this may reduce the patient's quality of life.

[0009] Porphyrin derivatives are known as photosensitizers used in PDT, and polyhematoporphyrin ether and talaporphyrin sodium have already been put to practical use. Considering the patient's QOL, a photosensitizer that can be localized by local administration and can be used in as small an amount as possible is required. In addition, doctors and patients would prefer a photosensitizer that can have a greater therapeutic effect with a single administration. [Prior art documents] [Non-patent literature]

[0010] [Non-Patent Document 1] Ink and clipping methods for preoperative marking with endoscopes (https: / / www.nissoken.com / jyohoshi / sc / 20181011mihon / 3.pdf) [Non-Patent Document 2] Yoshiaki Ozawa, Masahiko Murakami, (2020). Study of preoperative marking methods in laparoscopic rectal cancer surgery: Comparison of ink marking method and ICG fluorescence method. Showa Gakushikai Zasshi, 80.1:1-6. [Patent documents]

[0011] [Patent Document 1] JP 10-194998 Summary of the Invention [Problem to be solved by the invention]

[0012] In view of the problems with conventional marking agents described above, the present invention provides a copolymer and a method for producing the copolymer, which, when used to mark a specific site in biological tissue, can clearly and accurately mark the target site (typically a tumor site) over a relatively long period of time and enable the site to be confirmed from outside the tissue, as well as a tissue marking agent containing the copolymer. In view of the above-mentioned problems with conventional photodynamic therapy (PDT), the present invention also provides a photosensitizer that remains locally in cancer tissue for a long period of time after local administration. [Means for solving the problem]

[0013] The present inventors have found that a copolymer containing a constitutional unit having a quaternary ammonium cation and a constitutional unit having a porphyrin or a salt thereof can be bound to a tissue site to which it is locally administered, and can mark the target site for a relatively long period of time, and can also confirm the target site from outside the tissue. The present inventors have also conceived of utilizing the properties of this copolymer in PDT, and have found that by locally administering a photosensitizer to a target tissue (typically cancer tissue), the photosensitizer can be made to remain locally in the tissue for a long period of time, thereby enabling more effective PDT to be performed.

[0014] The present invention is based on such findings, and provides the following copolymer and a method for producing the same, as well as a tissue marking agent and a photosensitizer each containing the copolymer. [1] A copolymer comprising a repeating unit represented by the following formula (I) and a repeating unit represented by the following formula (II): [ka] (In the formula (I) or (II), R 1 and R 5 each independently represents a hydrogen atom or a linear or branched alkyl group having 1 to 5 carbon atoms, R 2 , R 3 and R 4 each independently represents a linear or branched alkyl group having 1 to 5 carbon atoms, a cycloalkyl group having 5 to 10 carbon atoms, an aralkyl group having 7 to 10 carbon atoms, or a group represented by the formula: R6-C(=O)- (wherein R 6 represents an OH group, a linear or branched alkyl group having 1 to 5 carbon atoms, a linear or branched alkoxyl group having 1 to 5 carbon atoms, or an unsubstituted or substituted amino group; L 1 and L 3 are each independently O or NH; L 2 and L 4 is a divalent group, Z is a group in which any one hydrogen atom has been removed from a porphyrin compound or a salt thereof, X represents an anion. [2] Said L 2 and L 4 each independently represents a divalent linear aliphatic hydrocarbon group having 1 to 5 carbon atoms, a divalent branched aliphatic hydrocarbon group having 3 to 5 carbon atoms, a divalent cyclic aliphatic hydrocarbon group having 5 to 10 carbon atoms, a divalent aromatic hydrocarbon group having 5 to 10 carbon atoms, -O-, -S-, -N(R7)- (wherein R 7 represents a hydrogen atom, or a linear or branched alkyl group having 1 to 12 carbon atoms), -C(=O)-, -C(=O)-O-, -OC(=O)-O-, -C(=O)-NH-, -OC(=O)-NH-, -S(=O)-, -S(=O)-O-, -S(=O)2-, -S(=O)2-O-, -CH=N-, or a combination thereof. [3] The copolymer according to [1] or [2], wherein the ratio of the number of repeating units represented by formula (II) to the total number of repeating units of the copolymer is 1 to 50%. [4] The copolymer according to any one of [1] to [3], wherein the ratio of the number of repeating units represented by formula (II) to the number of repeating units represented by formula (I) ((II) / (I)) is 1 / 1000 to 1 / 2. [5] The copolymer according to any one of [1] to [4], which has one or two constitutional units represented by formula (II). [6] The copolymer according to any one of [1] to [5], wherein the porphyrin compound is selected from the group consisting of mesoporphyrin, deuteroporphyrin, hematoporphyrin, protoporphyrin, uroporphyrin, coproporphyrin, cytoporphyrin, rhodoporphyrin, pyroporphyrin, phyloporphyrin; alkylcarboxyporphyrins such as heptacarboxyporphyrin, hexacarboxyporphyrin, and pentacarboxyporphyrin; and salts of these porphyrins. [7] R 1 and R5 each independently represents a hydrogen atom or a linear or branched alkyl group having 1 to 3 carbon atoms, R 2 , R 3 and R 4 each independently represents a linear or branched alkyl group having 1 to 3 carbon atoms, L 2 represents a linear or branched alkylene having 1 to 5 carbon atoms, L 4 represents a linear or branched alkylene having 1 to 5 carbon atoms; The copolymer according to any one of [1] to [6]. [8] R 1 、 R 2 , R 3 , R 4 and R 5 represents -CH3, L 1 represents -O-, L 3 represents -NH-, L 2 represents -CH2-CH2-, L 4 represents -CH2-CH2-CH2-, X represents Cl; The porphyrin compound is hematoporphyrin dihydrochloride. [7] The copolymer according to claim 1. [9] The copolymer according to any one of [1] to [8], which is water-soluble.

[10] The copolymer according to any one of [1] to [9], having a molecular weight (MW) of 1,000 to 100,000.

[11] A tissue marking agent comprising the copolymer according to any one of [1] to

[10] .

[12] The tissue marking agent according to

[11] , which is an aqueous solution.

[13] A tissue marking agent according to

[11] or

[12] for marking a localized portion of the digestive tract.

[14] The tissue marking agent according to

[13] for marking localized areas of the digestive tract extending from the stomach wall to the rectum.

[15] A tissue marking agent according to

[13] or

[14] for laparoscopic gastrointestinal surgery.

[16] A photosensitizer for photodynamic therapy, comprising the copolymer according to any one of [1] to

[10] .

[17] The photosensitizer according to

[16] , which is an aqueous solution.

[18] A pharmaceutical composition comprising the copolymer according to any one of [1] to

[10] .

[19] The pharmaceutical composition according to

[18] for the treatment of cancer.

[20] The pharmaceutical composition described in

[19] , wherein the cancer is gastrointestinal cancer.

[21] A method for tissue marking, comprising locally administering the tissue marking agent of

[11] to a target tissue site (typically a tumor site) and irradiating the tissue site with ultraviolet light of a predetermined wavelength (e.g., a wavelength of 350 nm to 420 nm) to excite the tissue marking agent.

[22] The tissue marking agent according to

[21] , wherein the tissue marking agent is an aqueous solution.

[23] The tissue marking method described in

[21] or

[22] , wherein the target tissue site is a specific site of the digestive tract.

[24] The tissue marking method described in

[23] , wherein the target tissue site is a specific site of the digestive tract extending from the stomach wall to the rectum.

[25] A tissue marking method according to

[23] or

[24] , which is carried out for laparoscopic gastrointestinal surgery.

[26] A photodynamic therapy comprising administering the photosensitizer described in

[16] to a target site of a subject and irradiating the target site of the subject with laser light of a predetermined wavelength (e.g., a wavelength of 630 nm to 660 nm).

[27] Photodynamic therapy as described in

[26] for the treatment of cancer.

[28] The photodynamic therapy described in

[27] , wherein the cancer is gastrointestinal cancer.

[29] Use of the copolymer according to any one of [1] to

[10] for preparing a tissue marking agent.

[30] The use described in

[29] , wherein the tissue marking agent is an aqueous solution.

[31] The use according to

[29] or

[30] , wherein the tissue marking agent is used to mark a localized portion of the digestive tract.

[32] The use described in

[31] , wherein the tissue marking agent is used to mark localized areas of the digestive tract from the stomach wall to the rectum.

[33] The use according to

[31] or

[32] , wherein the marking is performed for laparoscopic gastrointestinal surgery.

[34] Use of the copolymer according to any one of [1] to

[10] for preparing a photosensitizer for photodynamic therapy.

[35] The use described in

[34] , wherein the photosensitizer is an aqueous solution.

[36] Use of the photosensitizer according to

[16] for preparing a photodynamic therapy medicament.

[37] The use according to

[36] , wherein the medicament is for treating cancer.

[38] The use described in

[37] , wherein the cancer is gastrointestinal cancer.

[39] A method for producing the copolymer according to any one of [1] to

[10] , Compounds of formula (IA) and formula (IIA) [ka] R 1 、 R 2 , R 3 , R 4 , R 5 , L 1 , L 3 , L 2 , L 4 and X is as defined in any one of [1] to [8], The above-mentioned method further comprises a step of reacting the polymer obtained by the polymerization step with a porphyrin compound or a salt thereof.

[40] The method for producing the present invention described in

[39] , wherein the porphyrin compound is selected from the group consisting of mesoporphyrin, deuteroporphyrin, hematoporphyrin, protoporphyrin, uroporphyrin, coproporphyrin, cytoporphyrin, rhodoporphyrin, pyroporphyrin, phyloporphyrin; alkylcarboxyporphyrins such as heptacarboxyporphyrin, hexacarboxyporphyrin, and pentacarboxyporphyrin, and salts of these porphyrins. Effect of the Invention

[0015] The copolymer of the present invention exhibits excellent binding properties to biological tissues due to the positive charge derived from the structural unit having a quaternary ammonium cation, and can pinpoint and mark a target site for a long period of time of one week or more without diffusing after injection into tissue. In particular, since the copolymer always has a positive charge under various pH conditions, it exhibits excellent binding properties even in biological tissues having various pH environments, and can accurately mark a target site for a long period of time of one week or more in the gastrointestinal tract from the stomach wall to the rectum.

[0016] Furthermore, when tissue is marked using the copolymer of the present invention, the marked site can be clearly seen from outside the tissue by UV irradiation due to the constitutional unit having a porphyrin compound or a salt thereof.

[0017] In addition, the copolymer of the present invention localizes in target tissues such as cancer tissues for a long period of time and exhibits a high antitumor effect when irradiated with a laser. Therefore, the diffusion of the photosensitizer throughout the body is significantly reduced, and the dosage of the photosensitizer required for PDT treatment can be significantly reduced, which is expected to significantly reduce the burden on patients associated with PDT. In addition, PDT can be performed for a relatively long time with a single administration of the photosensitizer, and the therapeutic effect obtained by a single administration can be increased. [Brief description of the drawings]

[0018] [Figure 1]Chromatograms obtained by gel chromatography of the copolymer PMETAC-co-PAPMAA (HpD) and hematoporphyrin dihydrochloride (HpD) obtained in Example 1 are shown. The excitation wavelength is 400 nm, and the fluorescence wavelength is 635 nm. The solid line is a chromatogram of the copolymer PMETAC-co-PAPMAA (HpD) obtained in Example 1, and the dotted line is a chromatogram of hematoporphyrin dihydrochloride (HpD). The vertical axis indicates the fluorescence intensity, and the horizontal axis indicates the elution time. [Diagram 2] 1 shows the fluorescence spectrum of the copolymer PMETAC-co-PAPMAA (HpD) obtained in Example 1 when excited at 365 nm. [Diagram 3] 1 shows the absorption spectrum of the copolymer PMETAC-co-PAPMAA (HpD) (concentration: 0.25 mg / mL) obtained in Example 1. [Figure 4] 1 shows the absorption spectrum of 10 μM hematoporphyrin dihydrochloride (HpD). [Diagram 5] The photographs show the marking state of the site where the marking agents of Example 2 and Comparative Example 1 were locally injected into the mucosal side of the porcine colonic tissue from the serosal side (outside the digestive tract) and mucosal side (inner cavity side of the digestive tract). The photograph on the left shows the state where the marking agent of Comparative Example 1 was locally injected into the mucosal side of the colonic tissue, and the photograph on the second from the left shows the state where the marking agent of Comparative Example 1 was locally injected from the serosal side (outside the digestive tract). The photograph on the third from the left shows the state where the marking agent of Example 2 was locally injected into the mucosal side of the colonic tissue, and the photograph on the right shows the state where the marking agent of Example 2 was locally injected and irradiated with 365 nm ultraviolet light from the serosal side (outside the digestive tract). The arrows indicate the injection site. [Figure 6] 1 is a graph showing the change over time in the fluorescence intensity in the stomach after the marking agent of Comparative Example 2 (200 μM HpD) and the marking agent of Example 2 (200 μM PMETAC-co-PAPMAA (HpD), 5 mg / ml in terms of HpD) were locally injected into the anterior wall of the stomach of a rat. [Figure 7] The marking agents of Comparative Example 2 and Example 2 were locally injected into the anterior stomach wall of a rat one week later, and then 365 nm ultraviolet light was applied. The white arrow indicates the local injection site. In the photograph with a fluorescent filter, the fluorescence of porphyrin appears white. [Figure 8] 1 is a graph showing the daily changes in the body weight of rats after intraperitoneal injection of the marking agents of Comparative Example 2 and Example 2. [Figure 9] 1 is a graph showing daily changes in ALT, AST, CRE and BUN in rat blood after intraperitoneal injection of the marking agent of Comparative Example 2 and the marking agent of Example 2, respectively. A PBS-administered group was used as a control. [Figure 10] Photographs are shown of the adhesion state of the intestine observed one week after intraperitoneal injection of the marking agent of Comparative Example 2 and the marking agent of Example 2. The PBS-administered group was used as a control. [Figure 11] 11 is a graph showing the remaining state of each photosensitizer over time after the photosensitizers of Example 3 and Comparative Example 3 were administered to cancer tissues in Colon26 cancer-bearing mice. The remaining state of the photosensitizer was evaluated by measuring the fluorescence from the cancer tissues due to the photosensitizer. Fig. 11(A) shows the daily change in the fluorescence intensity from the cancer tissues when they were not irradiated with red visible light, and Fig. 11(B) shows the change when they were irradiated with red visible light. [Figure 12] 1 shows the change in size of cancer tissue in Colon26 tumor-bearing mice when PDT therapy was performed on the mice using the photosensitizers of Example 3 and Comparative Example 3. As a control, the change in size of cancer tissue when the photosensitizers of Example 3 and Comparative Example 3 were administered and then red visible light irradiation was not performed is also shown. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0019] The embodiments of the present invention will be described in detail below. However, the present invention is not limited to the following embodiments. <Copolymer of the Present Invention> The copolymer of the present invention (sometimes simply referred to as "copolymer") contains at least a repeating unit represented by the following formula (I) and a repeating unit represented by the following formula (II). [ka] (In the formula (I) or (II), R 1 and R 5 each independently represents a hydrogen atom or a linear or branched alkyl group having 1 to 5 carbon atoms, R 2 , R 3 and R 4 each independently represents a linear or branched alkyl group having 1 to 5 carbon atoms, a cycloalkyl group having 5 to 10 carbon atoms, an aralkyl group having 7 to 10 carbon atoms, or a group represented by the formula: R 6 -C(=O)-(in the formula, R 6 represents an OH group, a linear or branched alkyl group having 1 to 5 carbon atoms, a linear or branched alkoxyl group having 1 to 5 carbon atoms, or an unsubstituted or substituted amino group; L 1 and L 3 are each independently O or NH; L 2 and L 4 is a divalent group, Z is a group in which any one hydrogen atom has been removed from a porphyrin compound or a salt thereof, X represents an anion.

[0020] R 1 and R 5 preferably, each independently represents a hydrogen atom or a linear or branched alkyl group having 1 to 3 carbon atoms, and more preferably, each independently represents a hydrogen atom or a linear alkyl group having 1 to 3 carbon atoms.

[0021] R 2 , R 3 and R 4are preferably each independently a linear or branched alkyl group having 1 to 3 carbon atoms, a cycloalkyl group having 5 to 6 carbon atoms, an aralkyl group having 7 to 8 carbon atoms, or a group represented by the formula R 6 A group -C(=O)-, where R 6 represents an OH group, a linear or branched alkyl group having 1 to 3 carbon atoms, a linear or branched alkoxyl group having 1 to 3 carbon atoms, or an unsubstituted amino group. 2 , R 3 and R 4 More preferably, each independently represents a linear alkyl group having 1 to 3 carbon atoms.

[0022] L 1 is preferably O. Also, L 3 is preferably NH.

[0023] L 2 and L 4 are preferably each independently a divalent linear aliphatic hydrocarbon group having 1 to 5 carbon atoms, a divalent branched aliphatic hydrocarbon group having 3 to 5 carbon atoms, a divalent cyclic aliphatic hydrocarbon group having 5 to 10 carbon atoms, a divalent aromatic hydrocarbon group having 5 to 10 carbon atoms, -O-, -S-, -N(R 7 )-(wherein, R 7 represent a hydrogen atom or a linear or branched alkyl group having 1 to 12 carbon atoms), -C(=O)-, -C(=O)-O-, -OC(=O)-O-, -C(=O)-NH-, -OC(=O)-NH-, -S(=O)-, -S(=O)-O-, -S(=O)2-, -S(=O)2-O-, -CH=N-, or a combination of these, and more preferably each independently represents a divalent linear aliphatic hydrocarbon group having 1 to 5 carbon atoms, a divalent branched aliphatic hydrocarbon group having 3 to 5 carbon atoms, a divalent cyclic aliphatic hydrocarbon group having 5 to 6 carbon atoms, a divalent aromatic hydrocarbon group having 5 to 6 carbon atoms, -O-, -S-, -N(R7)- (wherein R 7represents a hydrogen atom or a straight or branched alkyl group having 1 to 5 carbon atoms), -C(=O)-, -C(=O)-O-, -OC(=O)-O-, -C(=O)-NH-, -OC(=O)-NH-, -S(=O)-, -S(=O)-O-, -S(=O)2-, -S(=O)2-O-, -CH=N-, or a combination thereof. L 2 and L 4 are more preferably each independently a divalent linear aliphatic hydrocarbon group having 1 to 5 carbon atoms, or a divalent branched aliphatic hydrocarbon group having 3 to 5 carbon atoms, and particularly preferably a divalent linear aliphatic hydrocarbon group having 1 to 3 carbon atoms.

[0024] Z is a group in which any one hydrogen atom has been removed from a porphyrin compound or a salt thereof. Porphyrin compounds are organic compounds having a cyclic structure formed by combining four pyrroles called porphins. Examples of the porphyrin compound include mesoporphyrin, deuteroporphyrin, hematoporphyrin, protoporphyrin, uroporphyrin, coproporphyrin, cytoporphyrin, rhodoporphyrin, pyroporphyrin, phyloporphyrin, or alkylcarboxyporphyrins such as heptacarboxyporphyrin, hexacarboxyporphyrin, and pentacarboxyporphyrin (preferably C1-10 alkylcarboxyporphyrin, more preferably C3-8 alkylcarboxyporphyrin).

[0025] The salts of the porphyrin compound include acid addition salts and base addition salts. The acid addition salts include inorganic acid salts and organic acid salts. The inorganic acid salts include salts derived from inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, and phosphoric acid, and the organic acid salts include salts derived from organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, and salicylic acid. The base addition salts include inorganic base salts and organic base salts. Examples of inorganic base salts include salts derived from inorganic bases such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, and aluminum. Examples of organic base salts include salts derived from organic bases such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, trifluoroacetyl, and ethanolamine.

[0026] The porphyrin compound is preferably hematoporphyrin, which has been actually put into practical use as a photosensitizer and has been confirmed to be safe. In addition, assuming that the copolymer of the present invention is injected into a specific tissue and used as a marking agent, it is preferable that the copolymer is water-soluble, and in this respect, Z is preferably a salt of a porphyrin compound, and as the salt, an acid addition salt is preferable, and an inorganic acid salt such as hydrochloride is more preferable.

[0027] X - Examples of the anion represented by the formula (I) include inorganic anions and organic anions. Examples of the inorganic anion include a fluorine anion, a chlorine anion, a bromine anion, an iodine anion, and a hydroxy anion. Examples of the organic anion include an alkoxy anion having 1 to 4 carbon atoms, a carboxy anion, an alkyl carboxy anion having 2 to 5 carbon atoms, and a hydrogen carbonate anion.

[0028] The copolymer may have repeating units other than those of formula (I) and formula (II), for example, it may contain a repeating unit in which Z in formula (II) is H. The copolymer may be any of a random copolymer, an alternating copolymer, and a block copolymer (diblock, triblock, or multiblock).

[0029] The number of repeating units represented by formula (II) in the copolymer is preferably within a predetermined range so that when the copolymer is used as a marking agent, a desired fluorescence intensity can be obtained, and the marking agent can be obtained as an aqueous solution, thereby reducing aggregation between the copolymers. Specifically, the ratio of the number of repeating units represented by formula (II) to the total number of all repeating units in the copolymer is preferably 0.01 to 50%, more preferably 1 to 30%, and particularly preferably 2 to 20%.

[0030] The ratio of the number of repeating units represented by formula (II) to the number of repeating units represented by formula (I) ((II) / (I)) is preferably from 1 / 100,000 to 1 / 1, more preferably from 1 / 1000 to 1 / 1, even more preferably from 1 / 100 to 1 / 2, and even more preferably from 1 / 70 to 1 / 10, from the viewpoints of adhesion to tissue.

[0031] A copolymer according to a preferred embodiment of the present invention has 1 to 10 repeating units represented by formula (II) in the copolymer, a more preferred embodiment has 1 to 5 repeating units, and a more preferred embodiment has 1 or 2 repeating units. Depending on the structure of the porphyrin moiety, when the number of porphyrin moieties in the copolymer is increased, not only does the copolymer become hydrophobic and insoluble in water, but the stacking of the porphyrin rings may tend to cause porphyrin fluorescence quenching. Interestingly, the fewer the number of porphyrin moieties contained in the copolymer, the stronger the fluorescence emitted, and a strong fluorescence intensity was confirmed in the copolymer having one or two repeating units represented by formula (II).

[0032] In the present specification, the ratio of the number of repeating units represented by formula (II) to the total number of all repeating units in the copolymer, and the ratio of the number of repeating units represented by formula (II) to the number of repeating units represented by formula (I) ((II) / (I)) are defined as follows: 1 It is determined by H NMR. More specifically, the copolymer is dissolved in deuterated methanol or deuterated water, 1The above ratio is calculated by measuring 1 H NMR and analyzing the integral value of the proton derived from the side chain. In the present specification, the term "water-soluble" means that the corresponding substance has a solubility of at least 1 g / L in pure water. The copolymer of the present invention preferably has a solubility of at least 5 g / L, more preferably at least 10 g / L, and particularly preferably at least 100 g / L.

[0033] The molecular weight (MW) of the copolymer is not particularly limited, and may be, for example, 300 to 1,000,000. However, since the molecular weight of the copolymer is one of the factors that can affect properties such as water solubility and viscosity, it is preferably 1,000 to 100,000, and more preferably 5,000 to 70,000, in consideration of use as a marking agent. As used herein, unless otherwise specified, "molecular weight" refers to weight average molecular weight (Mw). In addition, both weight average molecular weight (Mw) and number average molecular weight (Mn) refer to values ​​measured by gel filtration chromatography under the following conditions. Measuring device: Shimadzu 20AD Columns: TSK gel G3000PW and G5000PW columns Eluent: 0.5 M acetic acid aqueous solution (containing 20mM tetramethylammonium hydroxide pentahydrate) Standard material: Polyethylene glycol Flow rate: 0.5mL / min

[0034] <Method of producing the copolymer of the present invention> The copolymer of the present invention is Reaction Step 1: Formula (IA) and Formula (IIA) [ka] (In the formula, R 1 、 R 2 , R 3 , R4 , R 5 , L 1 , L 3 , L 2 , L 4 and X are the same as those defined in relation to formula (I) or (II), and the preferred and more preferred (and even more preferred, etc.) options for each are also as described above.) polymerizing the compound of formula (I); and Reaction step 2: A step of reacting the polymer obtained in reaction step 1 (hereinafter, sometimes referred to as an intermediate polymer) with a porphyrin compound. The composition is produced by a method comprising the steps of:

[0035] Reaction step 1 The polymerization reaction of the compounds of formula (IA) and formula (IIA) is carried out by reacting a mixture of the compounds of formula (IA) and formula (IIA), a thermal polymerization initiator, and a solvent. This polymerization reaction can be carried out, for example, at 70°C under an inert atmosphere such as nitrogen for 20 hours. The mixing ratio ((IIA) / (IA)) of the compound of formula (IA) to the compound of formula (IIA) is preferably adjusted according to the expected ratio of the repeating unit (I) to the total repeating units and the composition ratio between the repeating units (I) and (II), but can usually be in the range of 1 / 1000 to 1 / 2. In addition, it is preferable to set it in the range of 1 / 200 to 1 / 50 from the viewpoint of the required properties such as tissue adhesiveness. In addition, the structure control of random copolymers, alternating copolymers, and block copolymers may be carried out by a method generally known in the production of copolymers. The thermal polymerization initiator may be a water-soluble radical generator such as 4,4'-azobis(4-cyanovaleric acid), etc. The solvent may be water, ethanol, or a mixture of water and ethanol. The compounds of formula (IA) and formula (IIA) are commercially available compounds, and are available, for example, from Sigma-Aldrich Corporation or Tokyo Chemical Industry Co., Ltd.

[0036] When it is desired to obtain a copolymer with a desired molecular weight distribution, the polymer synthesized in reaction step 1 may be purified by dialysis using a dialysis membrane with a molecular weight cutoff of 1,000 to 100,000 depending on the desired molecular weight distribution.

[0037] Reaction step 2 By reacting the polymer obtained by the reaction step 1 with a porphyrin compound or a salt thereof, porphyrin can be introduced into the amino group of the repeating unit derived from the compound of formula (IIA) in the polymer. The introduction of porphyrin into the intermediate polymer can be carried out, for example, by reacting a mixture of the intermediate polymer, the porphyrin compound or a salt thereof, and a condensing agent in a buffer solution of pH 6 to 8 for 1 to 24 hours. The mixing ratio of the intermediate polymer and the porphyrin compound or a salt thereof is preferably adjusted according to the expected amount of the porphyrin compound or a salt thereof to be introduced, and is usually set to an amount in which the porphyrin compound or a salt thereof is 2 to 20 times the molar number per mole of the primary amino group, and from the viewpoint of production cost, it is preferably set to an amount in which the porphyrin compound or a salt thereof is 2 to 5 times the molar number. Examples of the condensing agent include N-hydroxysuccinimide and water-soluble carbodiimide hydrochloride.

[0038] <Uses of the Copolymer of the Present Invention> The copolymer of the present invention can be used as a tissue marking agent and can locally mark tissues of a living body. In a preferred embodiment, the copolymer is water-soluble, and a solution obtained by dissolving the copolymer in pure water, physiological saline, a buffer solution, etc. can be used as the tissue marking agent. In addition, the tissue marking agent of the present invention may contain various additives as long as it does not have a negative charge. The concentration of the copolymer in the solution may be usually 0.1 mg / mL to 100 mg / mL, and preferably 1 mg / mL to 10 mg / mL. Such a solution can be locally injected into tissue to mark a specific site, and the injection method is not particularly limited and may be a well-known or conventional method. After the marking agent is injected, ultraviolet light, preferably ultraviolet light having a wavelength of 350 nm to 370 nm, is irradiated to the injection site to excite the marking agent and generate fluorescence, thereby making it possible to confirm the injection site.

[0039] The copolymer of the present invention contains a repeating unit having a quaternary ammonium cation, and therefore always has a positive charge under various pH conditions, and therefore has excellent binding properties to all of the various tissues having environments with different pH levels, and is particularly suitable for marking the digestive tract having various pH levels, more specifically, the localized areas of the digestive tract from the stomach wall to the rectum. In addition, the copolymer of the present invention, which is derived from the repeating unit having a porphyrin skeleton, emits fluorescence when irradiated with UV light, and a specific site can be easily and clearly visually identified from the outside of the tissue. Therefore, the tissue marking agent of the present invention has the advantage that the site to be resected can be confirmed from the outside of the tissue before the operation in laparoscopic gastrointestinal surgery. In addition, since the copolymer of the present invention is retained in the tissue for at least one week after being injected into the tissue, the schedule from the injection of the marking agent to the resection operation of the marked tissue can be determined relatively flexibly. In addition, it has been confirmed that no side effects such as adhesion occur after injection into the tissue, and a highly safe marking agent is provided.

[0040] The copolymer of the present invention can also be used as a photosensitizer in PDT therapy, and can be used when performing PDT therapy on target tissues (e.g., cancer tissues). Therefore, in one embodiment, the present invention provides a pharmaceutical composition containing the copolymer of the present invention, particularly a pharmaceutical composition for cancer treatment. In a preferred embodiment, the copolymer is water-soluble, and a solution obtained by dissolving the copolymer in pure water, physiological saline, a buffer solution, or the like can be used as the photosensitizer. The photosensitizer and pharmaceutical composition in the solution may also contain various additives as long as they do not have a negative charge. The concentration of the copolymer in the solution may usually be 0.1 mg / mL to 100 mg / mL, and preferably 1 mg / mL to 10 mg / mL.

[0041] Such a solution is locally injected into a target tissue (e.g., cancer tissue) using, for example, a gastroscope, colonoscope, bronchoscope, or the like, and then the target tissue is irradiated with laser light (usually red visible light) of a predetermined wavelength (e.g., a wavelength of 630 nm to 660 nm), which induces a photochemical reaction in the copolymer of the present invention to generate active oxygen and denature or necrotize the cancer cells.

[0042] The copolymer of the present invention, which is derived from a repeating unit having a porphyrin skeleton, denatures and necrotizes target tissue (eg, tumor tissue) when irradiated with red visible light. The copolymer of the present invention also contains a repeating unit having a quaternary ammonium cation, and therefore always has a positive charge under various pH conditions. Therefore, it has excellent binding properties to all of the various tissues (including various cancer tissues) having different pH environments, and is particularly suitable for PDT of specific tissues (e.g., cancer tissues) of the digestive tract, which has various pH environments, more specifically, from the stomach wall to the rectum. The repeating unit having a quaternary ammonium cation also enables the copolymer of the present invention to be locally maintained in the cancer tissue for a long period of time when locally administered to the cancer tissue. As a result, the systemic diffusion of the photosensitizer is significantly reduced, and a more effective PDT therapy can be performed by administering a small amount of the photosensitizer once. This is expected to bring about a high therapeutic effect of PDT therapy without reducing the patient's QOL. EXAMPLES

[0043] The present invention will be described in more detail below with reference to examples, although the present invention is not limited to the following examples.

[0044] 1. Preparation of polycation-containing porphyrin derivatives Example 1 Copolymers of [2-(methacryloyloxy)ethyl]trimethylammonium chloride (METAC) and N-(3-aminopropyl) methacrylamide (APMAA) (PMETAC-co-PAPMAA) were synthesized by free radical polymerization, and then hematoporphyrin was reacted with the primary amino groups of APMAA in the copolymer to introduce porphyrin into the copolymer, obtaining [PMETAC-co-PAPMAA (HpD)]. [ka] Specifically, 10 mg of 4,4'-azobis(4-cyanovaleric acid) (ACVA, Sigma-Aldrich) as a thermal polymerization initiator, 50 mg of APMAA (Sigma-Aldrich), 200 mg of METAC (Sigma-Aldrich), and a mixed solvent of water and ethanol were added to a 2 mL flask, and after nitrogen bubbling, polymerization was carried out at 70°C for 20 hours under nitrogen (Reaction Step 1 above). Then, purification was carried out by dialysis against pure water using a dialysis membrane with a molecular weight cutoff of 3500, and the purified product was freeze-dried to recover a white powder copolymer (PMETAC-co-PAPMAA). The molecular weight of the obtained copolymer was measured by gel filtration chromatography under the following conditions, and the number average molecular weight (Mn) was 23,500, the weight average molecular weight (Mw) was 54,500, and the molecular weight distribution Mn / Mw was 2.3. Measuring device: Shimadzu 20AD Columns: TSK gel G3000PW and G5000PW columns Eluent: 0.5 M acetic acid aqueous solution (containing 20mM tetramethylammonium hydroxide pentahydrate) Standard material: Polyethylene glycol Flow rate: 0.5mL / min

[0045] Next, 2.5 mg of hematoporphyrin dihydrochloride (HpD, MedChem Express Company), 11.5 mg of N-hydroxysuccinimide (NHS, Incorporated), and 15.5 mg of water-soluble carbodiimide hydrochloride (WSCD·HCl, Peptide Institute Co., Ltd.) were added to 40 mg of the copolymer, and the mixture was reacted at room temperature for 20 hours in 500 mM phosphate buffer (pH 7.0) (reaction step 2 above). From the gel filtration chromatogram (fluorescence detection) shown in Figure 1, the chromatogram of PMETAC-co-PAPMAA (HpD) was earlier than the elution time of low molecular weight hematoporphyrin dihydrochloride (HpD), and there was no peak at the elution time of low molecular weight HpD, so it was confirmed that HpD was introduced into one molecule of PMETAC-co-PAPMAA, and unreacted low molecular weight HpD was removed by purification. Figure 2 shows the fluorescence spectrum of PMETAC-co-PAPMAA (HpD) obtained in Example 1. As with low molecular weight HpD, a fluorescent signal was confirmed at 600 nm to 700 nm when excited at 365 nm. FIG. 3 shows the absorption spectrum of the copolymer PMETAC-co-PAPMAA (HpD) obtained in Example 1, and FIG. 4 shows the absorption spectrum of low molecular weight hematoporphyrin dihydrochloride (HpD). A calibration curve was created using the absorbance at 400 nm of low molecular weight HpD, and the ratio of the number of repeating units PAPMAA (HpD) to the total number of all repeating units of the copolymer was calculated from the number average molecular weight (Mn) of the copolymer (PMETAC-co-PAPMAA). The ratio was 1 to 2%, and the composition ratio of PAPMAA (HpD) to PMETAC (PAPMAA (HpD) / PMETAC) was estimated to be 1 / 50 to 1 / 100. In addition, as described in the evaluation test described later, it was confirmed that PMETAC-co-PAPMAA (HpD) was soluble in pure water at a concentration of at least 5 mg / ml.

[0046] 2. Marking characteristic evaluation Example 2 The PMETAC-co-PAPMAA (HpD) obtained in Example 1 was dissolved in pure water to prepare an aqueous solution of 5 mg / ml (200 μM in terms of HpD) as a marking agent. Comparative Example 1 India ink (manufactured by Kaimeisha) used in clinical settings was used as is as a comparative marking agent. Comparative Example 2 Hematoporphyrin dihydrochloride (HpD, manufactured by MedChem Express Company) was dissolved in pure water to prepare a 200 μM aqueous solution, which was used as a marking agent. (1) Evaluation of visibility by comparison with the dotted ink method 10 μL of the marking agents of Example 2 and Comparative Example 1 were locally injected into the mucosal side of the large intestine tissue of a pig purchased from a meat processing company. With the marking agent of Comparative Example 1, the injection site was confirmed with the naked eye from the serosal side (outside the digestive tract) and mucosal side (inner cavity side of the digestive tract) immediately after injection, and with the marking agent of Example 2, the injection site was confirmed with the naked eye from the serosal side (outside the digestive tract) after irradiating it with 365 nm ultraviolet light. As shown in Figure 5, with the marking agent of Comparative Example 1, it was difficult to confirm the injection site from the serosal side (outside the digestive tract). Also, even when viewed from the mucosal side (inside the digestive tract), the boundary between the injection site and the surrounding tissues could not be clearly distinguished. On the other hand, with the marking agent of Example 2, when irradiated with ultraviolet light, the injection site could be clearly confirmed from the serosal side (outside the digestive tract), and the boundary between the injection site and the surrounding tissues could also be clearly distinguished. (2) Evaluation of the durability of marking in comparison with HpD The marking agent of Comparative Example 2 (200 μM HpD) and the marking agent of Example 2 (200 μM PMETAC-co-PAPMAA (HpD), 5 mg / ml) were each administered locally at 10 μL to the anterior wall of the stomach of a rat after abdominal incision to expose the stomach, and the fluorescence intensity was confirmed over time. When the anterior stomach wall of rats administered each marking agent was irradiated with 365 nm light, both the marking agents of Comparative Example 2 and Example 2 emitted strong fluorescent signals immediately after administration, but as shown in Figure 6, on the first day after administration, the rats administered the marking agent of Comparative Example 2 could no longer detect fluorescence at the administration site (signal strength was about 2%). In contrast, with the marking agent of Example 2, strong fluorescent signals were detected even on the 7th day after administration (see also Figure 7, which shows the fluorescent coloring state when the stomachs of rats administered the marking agents of Comparative Example 2 and Example 2 were irradiated with ultraviolet light 7 days later).

[0047] 3. Safety Testing Since the tissue marking agent for the digestive tract is administered locally using an endoscope, it may leak into the abdominal cavity during marking. Therefore, the tissue marking agent needs to be safe even if it leaks into the abdominal cavity. Therefore, the safety of the tissue marking agent of Example 2 when it leaks into the abdominal cavity was confirmed. Specifically, 100 μL of PBS, the marking agent of Comparative Example 2, and the marking agent of Example 2 were administered into the abdominal cavity of 6-week-old male Wistar rats, and the weight of each rat was measured daily. In addition, before administration of PBS or each marking agent, and 1 day and 7 days after administration, the tip of the rat's tail was cut, and blood was collected as heparinized blood, and the collected blood was centrifuged at 3000 rpm for 5 minutes at room temperature to recover plasma. Aspartate aminotransferase (AST), alanine aminotransferase (ALT), urea nitrogen (BUN), and creatinine (CRE) in the obtained plasma were measured using an animal clinical chemistry analyzer (Fuji Dry Chem NX7000V, manufactured by Fuji Film Corporation). In addition, after blood collection 7 days later, the rats were sedated with a triple anesthetic mixture, and the abdomen was incised along the midline to confirm the presence or absence of adhesion of organs. As a result, despite the administration of 10 times the dose used in the test to evaluate the marking properties, the marking agents of Comparative Example 2 and Example 2 did not cause any change in body weight (Figure 8), or in the values ​​of AST, ALT, BUN, and CRE, which indicate kidney and liver damage (Figure 9), and no adhesion of the intestinal tract was observed (Figure 10). Therefore, the high safety of PMETAC-co-PAPMAA (HpD) was demonstrated.

[0048] 4. Evaluation of photosensitizers for PDT therapy Example 3 The PMETAC-co-PAPMAA (HpD) obtained in Example 1 was dissolved in pure water to prepare a 5 mg / ml (200 μM in terms of HpD) aqueous solution, which was used as a photosensitizer. Comparative Example 3 Hematoporphyrin dihydrochloride (HpD, MedChem Express Company) was dissolved in pure water to prepare a 200 μM aqueous solution as a photosensitizer. (1) Colon26 tumor-bearing mice A mouse colon cancer cell line (Colon26, obtained from the RIKEN Cell Bank) was suspended in phosphate-buffered saline (PBS). This cell line (2 x 106 cells, 50 μL) was injected into the back of a mouse to obtain a Colonn26 tumor-bearing mouse.

[0049] (2) Cancer persistence test in tissue using IVIS imaging On the third day after the cell line injection, 50 μL of the photosensitizers of Example 3 and Comparative Example 3 were subcutaneously injected near the cancer tissue of Colon26 cancer-bearing mice, and the influence of irradiation with or without infrared-visible light after subcutaneous injection on the remaining state of the photosensitizer was examined. In detail, one of the Colon26 cancer-bearing mice was irradiated with red visible light (wavelength: 635 nm, intensity: 130 mW / cm2) for 10 minutes for three consecutive days from the day after the subcutaneous injection of each photosensitizer (i.e., the fourth day after the cell line injection), and the other Colon26 cancer-bearing mouse was not irradiated with red visible light after the subcutaneous injection of each photosensitizer. Using the IVIS imaging system, the fluorescence based on the photosensitizer from the cancer tissue of each Colon26 cancer-bearing mouse was measured, and the remaining state of the photosensitizer was evaluated. The results are shown in FIG. 11.

[0050] FIG. 11(A) shows the change in fluorescence intensity from the cancer tissue in a Colon26 cancer-bearing mouse injected with each photosensitizer when red visible light was not irradiated, and FIG. 11(B) shows the change when red visible light was irradiated. As can be seen from these graphs, the fluorescence intensity decreased with the number of days after the administration of the photosensitizer, but the mouse injected with the photosensitizer of Example 3 showed a higher fluorescence intensity than the mouse injected with the photosensitizer of Comparative Example 3. This shows that the photosensitizer of Example 3 remained in the cancer tissue more than the photosensitizer of Comparative Example 3. Moreover, a comparison between FIG. 11(A) and FIG. 11(B) shows that the photosensitizer of Example 3 remained in the cancer tissue without being affected by continuous irradiation with red visible light.

[0051] (3) Antitumor effect of PDT therapy Three days after the cell line injection, 50 μL of the photosensitizers of Example 3 and Comparative Example 3, and a PBS-administered group as a control, were subcutaneously injected near the cancer tissue of Colon26 cancer-bearing mice. After the subcutaneous injection, the Colon26 cancer-bearing mice were subjected to PDT therapy, and the daily change in the size of the cancer tissue (tumor size) was examined. In detail, the cancer tissue of the Colon26 cancer-bearing mice was irradiated with red visible light (wavelength: 635 nm, intensity: 130 mW / cm2) for 10 minutes every day for 15 days from the day of the subcutaneous injection. The irradiation with red visible light on the day of the subcutaneous injection was performed 10 minutes after the subcutaneous injection. The results are shown in FIG. 12.

[0052] For comparison, Fig. 12 also shows the change in cancer tissue size over time when PDT therapy was not performed (i.e., red visible light was not irradiated). Fig. 12 shows that cancer tissues tend to grow larger as the days go by, but surprisingly, it was found that the growth of cancer tissues was dramatically suppressed when PDT therapy was performed using the photosensitizer of Example 3.

[0053] From the above, it was demonstrated that the copolymer of the present invention can function as a photosensitizer for PDT therapy, and in particular, remains in cancer tissue for a long period of time and has a high antitumor effect.

Claims

1. A copolymer comprising a repeating unit represented by the following formula (I) and a repeating unit represented by the following formula (II): [Case 1] (In the formula (I) or (II), R1 and R5 each independently represent a hydrogen atom or a linear or branched alkyl group having 1 to 5 carbon atoms; R2, R3, and R4 each independently represent a linear or branched alkyl group having 1 to 5 carbon atoms, a cycloalkyl group having 5 to 10 carbon atoms, an aralkyl group having 7 to 10 carbon atoms, or a group of the formula: R6-C(═O)- (wherein R6 represents an OH group, a linear or branched alkyl group having 1 to 5 carbon atoms, a linear or branched alkoxyl group having 1 to 5 carbon atoms, or an unsubstituted or substituted amino group); L1 and L3 are each independently O or NH; L2 and L4 each independently represent a divalent linear aliphatic hydrocarbon group having 1 to 5 carbon atoms, a divalent branched aliphatic hydrocarbon group having 3 to 5 carbon atoms, a divalent cyclic aliphatic hydrocarbon group having 5 to 10 carbon atoms, a divalent aromatic hydrocarbon group having 5 to 10 carbon atoms, or a combination thereof; Z is a group in which any one hydrogen atom has been removed from a porphyrin compound or a salt thereof; X represents an anion.

2. 2. The copolymer according to claim 1, wherein the ratio of the number of repeating units represented by formula (II) to the total number of repeating units of the copolymer is 1 to 50%.

3. The copolymer according to claim 1 or 2, wherein the ratio ((II) / (I)) of the number of repeating units represented by formula (II) to the number of repeating units represented by formula (I) is 1 / 1000 to 1 / 2.

4. The copolymer according to any one of claims 1 to 3, having one or two constitutional units represented by formula (II).

5. The copolymer according to any one of claims 1 to 4, wherein the porphyrin compound is selected from the group consisting of mesoporphyrin, deuteroporphyrin, hematoporphyrin, protoporphyrin, uroporphyrin, coproporphyrin, cytoporphyrin, rhodoporphyrin, pyroporphyrin, phyloporphyrin, alkylcarboxyporphyrin, and salts of these porphyrins.

6. R1 and R5 each independently represent a hydrogen atom or a linear or branched alkyl group having 1 to 3 carbon atoms; R2, R3, and R4 each independently represent a linear or branched alkyl group having 1 to 3 carbon atoms; L2 represents a linear or branched alkylene having 1 to 5 carbon atoms; L4 represents a linear or branched alkylene having 1 to 5 carbon atoms; The copolymer according to any one of claims 1 to 5.

7. The copolymer according to any one of claims 1 to 6, which is water-soluble.

8. The copolymer according to any one of claims 1 to 7, having a weight average molecular weight (MW) of 1,000 to 1,000,000.

9. A tissue marking agent comprising the copolymer of any one of claims 1 to 8.

10. The tissue marking agent of claim 9 which is an aqueous solution.

11. The tissue marking agent according to claim 9 or 10 for marking a localized area of ​​the digestive tract.

12. The tissue marking agent according to claim 11, for marking a localized portion of the digestive tract extending from the stomach wall to the rectum.

13. 13. The tissue marking agent according to claim 11 or 12, for laparoscopic gastrointestinal surgery.

14. A photosensitizer for photodynamic therapy, comprising the copolymer according to any one of claims 1 to 8.

15. The photosensitizer of claim 14 which is in an aqueous solution.

16. A pharmaceutical composition comprising the copolymer according to any one of claims 1 to 8.

17. The pharmaceutical composition according to claim 16 for use in the treatment of cancer.

18. A method for producing the copolymer according to any one of claims 1 to 8, comprising the steps of: Compounds of formula (IA) and formula (IIA) below: [Case 2] R1 、 polymerizing a compound, wherein R2, R3, R4, R5, L1, L3, L2, L4 and X are as defined in any one of claims 1 to 6; and The method further comprises a step of reacting the polymer obtained by the polymerizing step with a porphyrin compound or a salt thereof.

19. 19. The method of claim 18, wherein the porphyrin compound is selected from the group consisting of mesoporphyrin, deuteroporphyrin, hematoporphyrin, protoporphyrin, uroporphyrin, coproporphyrin, cytoporphyrin, rhodoporphyrin, pyroporphyrin, phyloporphyrin, heptacarboxyporphyrin, hexacarboxyporphyrin, pentacarboxyporphyrin, and salts of these porphyrins.

Citation Information

Patent Citations

  • Macromolecular potassium ion fluorescent probe as well as preparation method and application thereof

    CN110642976A

  • Polymeric liquid crystal material

    JP1990086686A

  • Living body-marking preparation for surgery

    JP1998194998A

  • Supermolecular clathrate complex

    JP2009127044A

  • Polymer and contrast agent for photoacoustic imaging including the polymer

    JP2016169361A